The tech solution provides construction customers with an automated layout-as-a-service tool. Image via rugged-robotics.com

A Houston robotics startup working in the commercial construction field has closed its latest round of funding.

Rugged Robotics Inc. announced last week that it's raised $9.4 million in its series A round led by BOLD Capital Partners and Brick & Mortar Ventures. Riot Ventures, Morpheus, and Embark — all investors in the company's 2019 seed round — also contributed, as did Consigli Construction Company and Suffolk Technologies. To date, Rugged Robotics has raised $12 million.

“We are thrilled to be part of the Rugged team,” says Maxx Bricklin, partner at BOLD Capital, in a news release. “We looked at a number of companies in the space and became convinced that the Rugged team, technology and partner ecosystem would allow Rugged to dominate and capitalize on this significant and disruptive market opportunity.”

The fresh capital, the company shares in the release, will go toward scaling operations, expanding offerings, and continuing research and development.

Founded in 2018 by construction industry veteran Derrick Morse and former NASA engineer Logan Farrell, Rugged Robotics's Mark 1 product is modernizing the construction industry. The robot addresses challenges of field layout with a “layout Roomba” that marks architectural and engineering designs directly onto unfinished concrete floors. The company's early customers include Consigli Construction Co, Suffolk Construction, and Brasfield & Gorrie.

“When Derrick and Logan first visited our office, they clearly understood the problems we face and immediately separated themselves from typical technology startups. Their focus on solving real-world problems resonates with us, and we jumped at the opportunity to engage with them,” says Mike Haseltine, vice president and head of operations at Consigli. “Seeing their robots, their layouts, and their impact is inspiring. They’ve built something that’s going to change how we build buildings.”

While the concept of an autonomous layout solution isn't new, the Rugged Robotics approach is different from the industry standard in that it has a self-contained system that "enables multi-rover deployments, one-time set-ups that span an entire floor, and print zones that extend around and behind obstructions like columns, stairs, and elevators," per the news release. The company offers its customers the technology as a layout-as-a-service model.

“We’re building better,” says Morse, who serves as CEO, in the release. “We set out to modernize the construction industry, and to build practical solutions that solve the pain points contractors struggle with every day. We believe that layout is the ideal starting point. Layout is the beachhead for construction automation. It sits at the intersection of the digital and physical world, solves a huge problem, and unlocks the ability to deploy robotics onto job sites in a very meaningful way.”

The company is growing its team, which has included the onboarding of Mason Markee, the former director of mechanical engineering of Auris Health, who joined Rugged Robotics as vice president of engineering. Prior to Auris, Markee spent eight years at NASA as a robotics engineer.

“Mason has 15 years of years of robotics experience," says Farrell, the company's CTO, in the release. "I knew him at NASA, and we’re delighted to have him onboard at Rugged. He brings tremendous experience to the table. He is familiar with the entire product life cycle, from concept generation to final commercial production. He’s seen scale, and we’re excited by the rapid growth his technical expertise and leadership experience enables.”

The company has five engineering positions listed on LinkedIn.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”